MEDP vs PTGX
Medpace vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
64
Buy
| Metric | MEDP | PTGX |
|---|
| AI Score |
64
|
64
|
| Price |
$596.78
|
$151.99
|
| P/E Ratio |
34.82×
|
121.74×
|
| ROE |
98.3%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
99.9%
|
| Debt / Equity |
0.28×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
72.1
|
68.1
|
| Beta |
1.151
|
1.794
|
| Expected Upside |
+3.0%
|
—
|
AI Committee View
Current Innellis committee reasoning for MEDP versus PTGX.
The committee scores are tied.
MEDP and PTGX both score 64/100.
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical